Security Snapshot

JOHN HANCOCK EXCHANGE TRADED - MULTIFACTR SML (JHSC) Institutional Ownership

CUSIP: 47804J842

13F Institutional Holders and Ownership History from Q4 2017 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

48

Shares (Excl. Options)

7.07MFull value: 7,072,038 · shares · 30 Sep 2026

Price

$45.45

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+579,785
Value change
+$26,028,573
Number of holders
48
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$46.11
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • JHSC - JOHN HANCOCK EXCHANGE TRADED - MULTIFACTR SML is tracked under CUSIP 47804J842.
  • 48 institutions reported positions in Q3 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 86 to 48 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $563.04MFull value: $563,036,534 · USD · 30 Jun 2026
    to
    $321.41MFull value: $321,409,494 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 48 institutions filings for Q3 2026.

Open SEC evidence

Security key

47804J842

13F reference period

Q3 2026

13F holders

48

13D/G owners

0

CIK / CUSIP context first

As of 30 Sep 2026, 48 institutional investors reported holding
7.07MFull value: 7,072,038 · shares · 30 Sep 2026
shares of JOHN HANCOCK EXCHANGE TRADED - MULTIFACTR SML (JHSC).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
36
Headline period
Q3 2026
Rows shown
1-25 of 36
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 7,072,038 $321,409,494 +$26,028,573 $45.45 48
2026 Q2 11,594,014 $563,036,534 -$68,604,690 $48.56 86
2026 Q1 13,017,116 $558,196,634 +$4,490,594 $42.89 81
2025 Q4 12,914,876 $542,323,677 +$19,986,442 $41.99 75
2025 Q3 12,423,931 $519,929,477 +$30,219,381 $41.85 70
2025 Q2 11,717,935 $457,681,922 +$36,486,142 $39.05 67
2025 Q1 10,698,862 $398,764,136 -$83,312 $37.27 62
2024 Q4 10,818,594 $429,926,203 +$5,732,623 $39.74 64
2024 Q3 10,595,175 $425,233,660 +$37,559,055 $40.14 62
2024 Q2 9,659,601 $357,560,164 +$3,653,128 $37.02 57
2024 Q1 9,542,679 $366,403,997 -$24,093,833 $38.52 56
2023 Q4 10,183,863 $368,133,503 -$6,384,524 $36.57 54
2023 Q3 10,348,001 $334,158,017 +$20,579,495 $32.17 52
2023 Q2 9,747,195 $326,270,633 +$1,102,519 $33.46 53
2023 Q1 9,714,674 $309,802,758 -$2,021,063 $31.89 50
2022 Q4 9,663,710 $295,700,603 -$3,791,011 $30.59 47
2022 Q3 9,831,698 $276,293,940 -$7,751,903 $28.08 46
2022 Q2 10,056,377 $294,034,176 -$24,738,617 $29.22 43
2022 Q1 10,802,171 $370,682,776 +$8,358,561 $34.30 47
2021 Q4 10,560,204 $382,851,017 -$862,358 $36.25 42
2021 Q3 10,347,904 $357,546,571 -$9,820,375 $34.55 38
2021 Q2 10,641,511 $371,060,765 -$3,564,465 $34.88 39
2021 Q1 10,745,178 $363,585,908 -$197,615,065 $33.86 41
2020 Q4 16,589,374 $508,679,359 -$55,474,114 $30.66 38
2020 Q3 18,385,135 $448,226,747 +$2,515,945 $24.38 36
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .